fyi, the CFO just picked up shares at .94. however, the co. also just filed a shelf and recent sec filings indicate the need to raise at least $3mm in order to move their 2nd drug candidate CPP-115 to clinical trials so any move to the upside may be capped by upcoming dilution.
Long-term I see this company being bought out by Lundbeck in order to protect their $900 million investment in the antiepileptic drug Sabril (Lundbeck bought Ovation in 2009)
News 
Market Data 
Discover 
AI
